Vortioxetine in the Treatment of Mood Disorders Associated with Burning Mouth Syndrome: Results of an Open-Label, Flexible-Dose Pilot Study.

OBJECTIVE To evaluate the efficacy of a new multimodal antidepressant, vortioxetine (VO), in the management of burning mouth syndrome (BMS). DESIGN Longitudinal single-assessment open-label pilot study. SETTING University hospital. Subjects. Thirty BMS patients were enrolled. METHODS BMS patients were treated with topical clonazepam and a flexible dose of VO (10 mg, 15 mg, or 20 mg). The visual analog scale (VAS), the Total Pain Rating Index (T-PRI), the Hamilton Rating Scales for Depression (HAM-D) and Anxiety (HAM-A), and the Pittsburgh Sleep Quality Index (PSQI) were performed at baseline (time 0) and after two (time 1), four (time 2), six (time 3), and 12 months (time 4) of treatment. Descriptive statistics and the Wilcoxon nonparametric test for two paired samples were used. RESULTS The BMS patients showed a statistically significant improvement in VAS and T-PRI scores from baseline (median [interquartile range {IQR}] = 10.0 [10-10] and 22.0 [20-24], respectively) to time 4 (median [IQR] = 0.0 [0-0] and 8.0 [7-9], P < 0.001, respectively). Similarly, the HAM-A and HAM-D and PSQI scores showed an improvement from time 0 (median [IQR] = 20 [15.8-22], 19 [16-20.3], and 4.0 [4-7.3], respectively) to time 4 (median [IQR] = 6.0 [6-7], 6.0 [6-7], and 3.0 [3-4], respectively, P < 0.001). CONCLUSIONS VO is efficacious and well tolerated in the treatment of BMS in firstline therapy on account of its better receptor pharmacological profile and in second-line treatment for patients who have only partially responded or have reported adverse effects to previous treatments.

• Publication year

  2019

• Venue

  Pain medicine (Malden, Mass.)

• Publication date

  2019-07-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/pm/pnz120PMID 31343684
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis.

  2018cited by this paper
• Plasma IL‐8 signature correlates with pain and depressive symptomatology in patients with burning mouth syndrome: Results from a pilot study

  2018cited by this paper
• Understanding of Burning Mouth Syndrome Based on Psychological Aspects.

  2018cited by this paper
• Are pharmacological treatments for oro-facial pain effective?

  2018cited by this paper
• The association between burning mouth syndrome and sleep disturbance: A case-control multicentre study.

  2018cited by this paper
• The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram.

  2018cited by this paper
• Use of antidepressants in dentistry: A systematic review.

  2018cited by this paper
• Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis

  2018cited by this paper
• Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD)

  2018cited by this paper
• Overlaps in pharmacology for the treatment of chronic pain and mental health disorders

  2018cited by this paper
• Pain-relieving effects of clonazepam and amitriptyline in burning mouth syndrome: a retrospective study.

  2017cited by this paper
• Safety and tolerability of topical clonazepam solution for management of oral dysesthesia.

  2017cited by this paper
• Role of psychological factors in burning mouth syndrome: A systematic review and meta-analysis

  2017cited by this paper
• In vivo and in vitro effects of vortioxetine on molecules associated with neuroplasticity

  2017cited by this paper
• Pharmacokinetics, Safety, and Tolerability of Vortioxetine Following Single‐ and Multiple‐Dose Administration in Healthy Japanese Adults

  2017cited by this paper
• Duloxetine Plasma Concentrations and Its Effectiveness in the Treatment of Nonorganic Chronic Pain in the Orofacial Region

  2017cited by this paper
• Vortioxetine: Clinical Pharmacokinetics and Drug Interactions

  2017cited by this paper
• Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older

  2016cited by this paper
• Burning Mouth Syndrome.

  2016cited by this paper
• The Relationship Between Sociodemographic Characteristics and Clinical Features in Burning Mouth Syndrome.

  2015cited by this paper
• Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature

  2015cited by this paper
• A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.

  2015cited by this paper
• A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD

  2015cited by this paper
• Involvement of 5-HT7 receptors in vortioxetine's modulation of circadian rhythms and episodic memory in rodents

  2015cited by this paper
• Five Patients With Burning Mouth Syndrome in Whom an Antidepressant (Serotonin-Noradrenaline Reuptake Inhibitor) Was Not Effective, but Pregabalin Markedly Relieved Pain.

  2015cited by this paper
• Role of the dentist in the management of orofacial pain.

  2015cited by this paper
• Use of Selective Serotonin Reuptake Inhibitors in the Treatment of Burning Mouth Syndrome

  2014cited by this paper
• New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder

  2014cited by this paper
• Treatment of Burning Mouth Syndrome With Amisulpride

  2012cited by this paper
• A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder

  2012cited by this paper
• A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

  2011cited by this paper
• The impact of burning mouth syndrome on health-related quality of life

  2011cited by this paper
• Structural changes in the hippocampus in major depressive disorder: contributions of disease and treatment.

  2010cited by this paper
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care

  2007cited by this paper
• The effect of levosulpiride in burning mouth syndrome.

  2007cited by this paper
• Small fibre neuropathies

  2005cited by this paper
• Altered dopamine D2 receptor binding in atypical facial pain

  2003cited by this paper
• The burning mouth syndrome remains an enigma.

  1995cited by this paper

• Vortioxetine: A comprehensive profile.

  2026cites this paper
• Management strategies for burning mouth syndrome: a comprehensive review

  2026cites this paper
• Managing Burning Mouth Syndrome: Current and Future Directions

  2025cites this paper
• Comparative study on the analgesic effect of vortioxetine and other antidepressants in the streptozotocin mouse model of painful diabetic neuropathy

  2025cites this paper
• Effectiveness of Vortioxetine in Relieving Chronic Pain in Patients with Associated Depression in a Spanish Population

  2025influential citation
• Burning Mouth Syndrome: Unlocking the Future of Pharmacological Treatment.

  2025cites this paper
• Chronic orofacial pain and pharmacological management-a clinical guide.

  2025cites this paper
• The efficacy of vortioxetine in the acute treatment of major depressive disorder: A systematic review and meta-analysis

  2025cites this paper
• Burning mouth syndrome: updates on pathogenesis and diagnostic algorithms

  2025cites this paper
• What's Hot, What's Not: Review of Pharmacological Options for Managing Burning Mouth Syndrome.

  2025cites this paper
• An overview of the safety and efficacy of LX-9211 in treating neuropathic pain conditions

  2024cites this paper
• BLUEPRINT PERSONA AND INFORMATION AND COMMUNICATION TECHNOLOGY INTERVENTIONS: ADDRESSING UNMET NEEDS IN BURNING MOUTH SYNDROME CARE.

  2024cites this paper
• Effectiveness of Vortioxetine in Patients with Major Depressive Disorder Associated with Chronic Pain: An Observational Study in a Spanish Population

  2024cites this paper
• The Role of Vortioxetine in the Treatment of Depressive Symptoms in General Hospital Psychiatry: A Case-Series and PRISMA-Compliant Systematic Review of the Literature

  2024cites this paper
• Vortioxetine versus SSRI/SNRI with Pregabalin Augmentation in Treatment-Resistant Burning Mouth Syndrome: A Prospective Clinical Trial

  2024influential citation
• Catecholaminergic and Cholinergic Systems Mediate Beneficial Effect of Vortioxetine on Diabetes-Induced Neuropathic Pain

  2023cites this paper
• Salivary Complaints in Burning Mouth Syndrome: A Cross Sectional Study on 500 Patients

  2023cites this paper
• Dental sleep-related conditions and the role of oral healthcare providers: A scoping review.

  2022cites this paper
• Role of vortioxetine in the treatment of neuropathic pain.

  2022cites this paper
• BURNING MOUTH DISEASE, MODERN TREATMENT AND CLINICAL MANAGEMENT: A NARRATIVE REVIEW

  2022cites this paper
• Treatments for Burning Mouth Syndrome: A Network Meta-analysis

  2022cites this paper
• The Analgezic Effect of Vortioxetine on somatic and visceral Pain using the mouse models

  2022cites this paper
• Vortioxetine Improves Depressive Symptoms and Cognition in Parkinson’s Disease Patients with Major Depression: An Open-Label Prospective Study

  2022cites this paper
• Serotonergic Neurotransmission System Modulator, Vortioxetine, and Dopaminergic D2/D3 Receptor Agonist, Ropinirole, Attenuate Fibromyalgia-Like Symptoms in Mice

  2021cites this paper
• A Qualitative Systematic Review of the Association of Sleep Disturbances with Burning Mouth Syndrome: An Overlooked Relationship

  2021cites this paper
• Vortioxetine as an analgesic in preclinical inflammatory pain models: Mechanism of action

  2021cites this paper
• Role of vortioxetine in the treatment of neuropathic pain.

  2021cites this paper
• Treatment Modalities of Burning Mouth Disease

  2021cites this paper
• Management of Burning Mouth Disease

  2021cites this paper
• Vortioxetine as a new frontier in the treatment of chronic neuropathic pain: a review and update

  2021cites this paper
• Burning Fog: Cognitive Impairment in Burning Mouth Syndrome

  2021cites this paper
• A Case of Major Depression with Burning Mouth Syndrome and Tinnitus Successfully Treated with Vortioxetine

  2021cites this paper
• Vortioxetine reduces pain hypersensitivity and associated depression-like behavior in mice with oxaliplatin-induced neuropathy.

  2020cites this paper
• Evaluating the Suitability and Potential Efficiency of Cannabis sativa Oil for Patients with Primary Burning Mouth Syndrome: A Prospective, Open-Label, Single-Arm Pilot Study.

  2020cites this paper
• Vortioxetine versus other antidepressants in the treatment of Burning Mouth Syndrome: an open-label randomized trial.

  2020cites this paper
• Assessment of Oral Health-related Quality of Life, measured by OHIP-14 and GOHAI, and psychological profiling in Burning Mouth Syndrome: a case-control clinical study.

  2019cites this paper